Patient retention in rare disease clinical trials is crucial when considering the limited patient numbers available. It has been reported that 18% of patients randomised into a clinical trial end up withdrawing.* This number is predicted to be even higher in rare disease clinical trials. There is a considerable burden to the patient/their family to take part in a clinical trial.
This audit aims to determine if commissioning a specialised clinical trial support service impacts on study retention rates in rare disease studies.
*https://forteresearch.com/news/infographic/infographic-retention-in-clinical-trials-keeping-patients-on-protocols/
